Literature DB >> 2589197

Comparison of adenosine and verapamil for termination of paroxysmal junctional tachycardia.

C Garratt1, N Linker, M Griffith, D Ward, A J Camm.   

Abstract

The effects of intravenous adenosine and intravenous verapamil on paroxysmal junctional tachycardia were compared in 20 patients undergoing invasive cardiac electrophysiologic study. In 13 patients the diagnosis was of a reentrant tachycardia using an extranodal accessory connection (atrioventricular [AV] reentrant tachycardia); 5 of these patients had overt preexcitation in sinus rhythm, 4 had concealed accessory connections and 4 had latent or intermittent preexcitation. In 7 patients the diagnosis was of an AV nodal reentrant tachycardia. Administration of adenosine resulted in termination of tachycardia in all 20 patients at a mean dose of 0.125 mg/kg (range 0.05 to 0.20). Although termination of tachycardia was frequently accompanied by atrial and ventricular premature complexes, no significant arrhythmias were observed after conversion. Administration of verapamil (0.145 mg/kg) resulted in termination of tachycardia in 19 of 20 patients but was followed by symptomatic arrhythmias in 2: preexcited atrial flutter in 1 patient and preexcited atrial tachycardia in another. Latent or intermittent preexcitation was unmasked in 4 of 4 patients immediately after termination of tachycardia by adenosine. Termination of tachycardia by verapamil revealed preexcitation in only 1 of these 4 patients. Analysis of results in terms of successful termination of tachycardia, absence of significant arrhythmias after conversion and unmasking of latent or intermittent preexcitation reveals that adenosine therapy was satisfactory in all 20 patients, whereas verapamil was satisfactory in only 14 of the 20 patients (p less than 0.05). All 6 of the patients with unsatisfactory responses to verapamil had AV reentrant tachycardia. These results suggest that adenosine has particular advantages over verapamil as acute treatment for patients presenting with an AV reentrant tachycardia.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2589197     DOI: 10.1016/0002-9149(89)90573-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

1.  Terminating paroxysmal supraventricular tachycardias with adenosine.

Authors:  J Nathan
Journal:  West J Med       Date:  1991-09

2.  Dose and rate-dependent effects of adenosine on atrial action potential duration in humans.

Authors:  J Tebbenjohanns; B Schumacher; D Pfeiffer; W Jung; B Lüderitz
Journal:  J Interv Card Electrophysiol       Date:  1997-02       Impact factor: 1.900

Review 3.  Adenosine. An evaluation of its use in cardiac diagnostic procedures, and in the treatment of paroxysmal supraventricular tachycardia.

Authors:  D Faulds; P Chrisp; M M Buckley
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

4.  Evidence for a cooperation between adenosine A2 receptors and beta 1-adrenoceptors on cardiac automaticity in the isolated right ventricle of the rat.

Authors:  J Hernandez; F Pinto; M A Figueira; J A Riberio
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

5.  Involvement of alpha-adrenoceptors in the excitatory effect of the A2 adenosine receptors agonist 5'-N-ethylcarboxamidoadenosine (NECA) on cardiac automaticity in the isolated right ventricle of the rat.

Authors:  J Hernández; F Pinto; J A Ribeiro
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-12       Impact factor: 3.000

Review 6.  The therapeutic and diagnostic cardiac electrophysiological uses of adenosine.

Authors:  A D Malcolm; C J Garratt; A J Camm
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

7.  Haemodynamic deterioration after treatment with adenosine.

Authors:  R P Cowell; V E Paul; C D Ilsley
Journal:  Br Heart J       Date:  1994-06

Review 8.  Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia.

Authors:  Samer Alabed; Ammar Sabouni; Rui Providencia; Edmond Atallah; Mohammed Qintar; Timothy Ja Chico
Journal:  Cochrane Database Syst Rev       Date:  2017-10-12

9.  Volatile and bioactive compounds in opercula from Muricidae molluscs supports their use in ceremonial incense and traditional medicines.

Authors:  Bijayalakshmi Devi Nongmaithem; Peter Mouatt; Joshua Smith; David Rudd; Michael Russell; Caroline Sullivan; Kirsten Benkendorff
Journal:  Sci Rep       Date:  2017-12-12       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.